Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited drug treatment options especially with regard to inotropic therapy. Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myos...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2018-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|